Second Quarter 2025 Total Revenues of $825 million (+16% Y/Y and +17% at Constant Currency Y/Y) Second Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $1.23 (+124% Y/Y) Second Quarter 2025 Non-GAAP Diluted EPS of $1.44 (+50% Y/Y) BioMarin Completes Acquisition of Inozyme in July 2025 ; Pivotal Data from Lead Indication Expected 1H'26 BMN 333 Exceeds Targeted Exposures of Free C-type Natriuretic Peptide (CNP) in Healthy... Read More

SAN RAFAEL, Calif. , Aug. 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Ian T. Clark to the company's Board of Directors, effective today, August 1, 2025 . Mr. Clark served as Chief Executive Officer of Genentech and a member of the company's Board of Directors from 2010 until his retirement in 2016. Under his leadership, Genentech launched 15 new drugs. Prior to... Read More

SAN RAFAEL, Calif. , July 22, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 4, 2025 , at 4:30 p.m. ET to discuss second quarter 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-715-9871 International... Read More

SAN RAFAEL, Calif. , July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million . The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine... Read More

Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No new safety signals observed SAN RAFAEL, Calif. , June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN ® (valoctocogene roxaparvovec-rvox) were... Read More

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected in Early 2026 with Potential Launch in 2027; Additional Clinical Programs to Expand to Patients of all Ages Potential First-in-Disease Treatment for ENPP1 Deficiency Conference Call and Webcast Scheduled Today at 8:45 a.m. ET... Read More

New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits SAN RAFAEL, Calif. , May 12, 2025... Read More

First Quarter 2025 Total Revenues of $745 million (+15% Y/Y and +17% at Constant Currency Y/Y) First Quarter 2025 GAAP Diluted Earnings Per Share (EPS) of $0.95 (+107% Y/Y) First Quarter 2025 Non-GAAP Diluted EPS of $1.13 (+59% Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif. , May 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the... Read More

SAN RAFAEL, Calif. , April 17, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, 2025 , at 4:30 p.m. ET to discuss first quarter 2025 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144 International... Read More

Company plans to submit for regulatory approval later this year SAN RAFAEL, Calif. , April 2, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering in blood Phe levels in adolescents aged 12-17 with phenylketonuria (PKU) compared to diet alone.... Read More

New data also to be presented for PALYNZIQ ® (pegvaliaise-pqpz), reinforcing its value in sustaining blood Phe level reduction and improving health-related quality of life for adults with phenylketonuria SAN RAFAEL, Calif. , March 20, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive new data from studies of VOXZOGO ® (vosoritide) in children with achondroplasia and in ongoing clinical... Read More

SAN RAFAEL, Calif. , Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025 , at 6:50 AM PT / 9:50 AM ET in Boston, MA. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/ . An archived version of the remarks will... Read More

SAN RAFAEL, Calif. , Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert , former chairman, president and chief executive officer of Horizon Therapeutics, to the company's Board of Directors, effective Feb. 24, 2025 . Mr. Walbert led Horizon, a company that focused on medicines for rare diseases, from its founding in 2008 to acquisition... Read More

Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 2025 4Q 2024 Total Revenues of $747 million (+16% Y/Y and +21% at Constant Currency Y/Y); FY 2024 Total Revenues of $2.85 billion (+18% Y/Y and +22% at Constant Currency Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif. , Feb.... Read More

SAN RAFAEL, Calif. , Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025 , at 4:30 p.m. ET to discuss fourth quarter and full-year 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number:... Read More

SAN RAFAEL, Calif. , Jan. 13, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany . The patent covers long-acting variants of C-Type Natriuretic Peptide (CNP). The legal action, which would result in a decision in the... Read More

SAN RAFAEL, Calif. , Jan. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will present at the 43rd Annual J.P. Morgan Conference on Monday, January 13, 2024 , at 9:00 am PT / 12:00 pm ET , in San Francisco, California . An audio webcast of the presentation will be available live. You can access the webcast at:... Read More

SAN RAFAEL, Calif. , Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO ® (vosoritide) in children with achondroplasia. These results, as well as data from the investigational research program for VOXZOGO in hypochondroplasia, were presented at the 62nd Annual European Society for Paediatric... Read More

UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at 7:00 am PST SAN RAFAEL, Calif. , Nov. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences. An audio webcast of the presentation will... Read More

Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y); Year-to-date 2024 Total Revenues of $2.11 billion (+19% Y/Y and +23% at Constant Currency Y/Y) During the Quarter, Strong Demand Drove 54% Y/Y Revenue Growth for VOXZOGO ® During the Quarter, Revenues from Enzyme Therapies Portfolio Increased 27% Y/Y Third Quarter 2024 GAAP Diluted Earnings Per Share (EPS) of $0.55 (+162% Y/Y);... Read More

SAN RAFAEL, Calif. , Oct. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, October 29, 2024 , at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144... Read More

Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related Development Across Multiple Genetic Skeletal Conditions New Data Highlight Meaningful Improvements in Health-Related Quality of Life for Children with Achondroplasia Investigator-Led Study Shows Significant Increases in Bone Length While Maintaining Bone Strength in Children with... Read More

NEW YORK , Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and other members of BioMarin's leadership team provided an overview of the company's new corporate strategy to deliver sustained value creation and introduced longer-term Total Revenue and Non-GAAP Operating Margin guidance. A copy of the... Read More

NEW YORK , Sept. 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York. The event begins at 10:30 a.m. Eastern Time and can be accessed virtually here . Led by President and Chief Executive Officer Alexander Hardy , the event will feature presentations from BioMarin's leadership team as they introduce strategic priorities that underscore BioMarin's commitment to... Read More

SAN RAFAEL, Calif. , Aug. 29, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller , Executive Vice President, Chief Financial Officer of BioMarin will present at the 22 nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5, 2024 , at 7:45 AM PT / 10:45 AM ET in New York, NY . An audio webcast of the presentation will be available live. You can access... Read More

Greg Friberg, M.D., Appointed EVP, Chief Research & Development Officer as Hank Fuchs, M.D., Will Retire After 15 Years at Company James Sabry, M.D., Ph.D., Appointed EVP, Chief Business Officer SAN RAFAEL, Calif. , Aug. 21, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the appointments of Greg Friberg , M.D., as Executive Vice President, Chief Research & Development Officer, succeeding... Read More

Event to be webcast live and a replay will be available SAN RAFAEL, Calif. , Aug. 19, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host an Investor Day with financial analysts and institutional investors on Wednesday, September 4, 2024 , in New York City from 10:30 am to 1:00 pm Eastern Time . The event will feature presentations from members of the executive management team and will highlight... Read More

Second Quarter 2024 Total Revenues of $712 million (+20% Y/Y and +25% at Constant Currency Y/Y); First Half 2024 Total Revenues of $1.36 billion (+14% Y/Y and +19% at Constant Currency Y/Y) Second Quarter 2024 GAAP Diluted EPS of $0.55 (+90% Y/Y); First Half 2024 GAAP Diluted EPS of $1.01 (+80% Y/Y) Second Quarter 2024 Non-GAAP Diluted Earnings per Share (EPS) of $0.96 (+78% Y/Y); First Half 2024 Non-GAAP Diluted EPS of... Read More

Strategic Focus will Reduce Operating Expenses with the Goal of Achieving ROCTAVIAN Profitability by End of 2025 BioMarin to Provide Continued Monitoring and Support to Those Treated in Clinical Trials and Commercially SAN RAFAEL, Calif. , Aug. 5, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced it will make changes to its ROCTAVIAN ® business to focus commercial operations on three markets,... Read More

Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, Calif. , July 24, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for BRINEURA ® (cerliponase alfa) to slow the loss of ambulation in children of... Read More

SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 5, 2024 , at 4:30 p.m. ET to discuss second quarter 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-596-4144 International... Read More

New Investigator-Led Study Shows VOXZOGO Significantly Increased Bone Length While Maintaining Bone Strength Through 5 Years of Observation in Children with Achondroplasia Phase 2 and 3 Data on VOXZOGO Demonstrate Safety, Efficacy and Impact on Proportionality and Health-Related Quality of Life for Children with Achondroplasia New Research Underscores Unmet Medical Needs of People with Hypochondroplasia SAN RAFAEL, Calif. ,... Read More

Data from Longest and Largest Hemophilia Gene Therapy Study Show Durable and Sustained Bleed Control and Factor VIII Expression Maintained Four Years Post-ROCTAVIAN Infusion Additional Data Show Meaningful Impact of ROCTAVIAN on Health-Related Quality of Life (HRQoL) SAN RAFAEL, Calif. , June 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that new data supporting the long-term safety and... Read More

SAN RAFAEL, Calif. , May 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024 , at 10:00am PT / 1:00pm ET , in Las Vegas, Nevada . An audio webcast of the presentation will be available live. You can access the webcast at:... Read More

Investigator-Sponsored Phase 2 Study Demonstrated Positive Results in Children with Noonan Syndrome, Idiopathic Short Stature and Other Growth-Related Conditions BioMarin-Sponsored Phase 3 Data Show Notable Mean Annualized Growth Velocity Increases in Children with Achondroplasia Who Started Treatment During Adolescence SAN RAFAEL, Calif. , May 4, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced... Read More

First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO ® Net Product Revenues of $153 Million in Q1'24 (+74% Y/Y); Children Treated Increased Over 100% Y/Y For Full-year 2024 Guidance, Total Revenues Reaffirmed, Non-GAAP Operating Margin and Non-GAAP EPS Raised... Read More

SAN RAFAEL, Calif. , April 10, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 24 , at 4:30 p.m. ET to discuss first quarter 2024 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-330-3556 International... Read More

Investigator-Sponsored Phase 2 Study Demonstrated Positive Results for VOXZOGO in Children with Hypochondroplasia New Analyses Highlight VOXZOGO 7-year Data and Improvement on Quality of Life in Children with Achondroplasia SAN RAFAEL, Calif. , March 12, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO ® (vosoritide)... Read More

Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif. , March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations,... Read More

Cowen 44 th Annual Healthcare Conference on March 5 Leerink Partners Global Biopharma Conference on March 11 Jefferies Biotech on the Bay Summit on March 12 Barclays 26 th Annual Global Healthcare Conference on March 12 SAN RAFAEL, Calif. , March 1, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management is scheduled to participate in four upcoming investor conferences in March. Cowen 44... Read More

Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted Earnings per Share of $2.08 (+36% Y/Y) VOXZOGO ® Net Revenues of $146 Million in Q4'23 (+118% Q/Q) and $470 Million for FY'23 (+178% Y/Y) BioMarin's 2024 Financial Outlook Reflects Anticipated Double-digit Total Revenue Growth, Significant Non-GAAP Operating Margin... Read More

SAN RAFAEL, Calif. , Feb. 8, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 22 , at 4:30 p.m. ET to discuss fourth quarter and full-year 2023 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-330-3073... Read More

New Seven-Year Follow-Up Phase 2 Study Results Showed Durable Hemostatic Benefit for Adults with Severe Hemophilia A SAN RAFAEL, Calif. , Feb. 6, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) will be presented at the 2024 European... Read More

SAN RAFAEL, Calif. , Jan. 3, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy , President and Chief Executive Officer of BioMarin, will present at the 42 nd Annual J.P. Morgan Conference on Monday January 8, 2024 , at 10:30 am PT / 1:30 pm ET , in San Francisco , California. An audio webcast of the presentations will be available live. You can access the webcasts at:... Read More

Board Approves Appointment of Three New Independent Directors Company Establishes Strategic and Operating Review Committee of the Board BioMarin Enters into Cooperation and Information Sharing Agreements with Elliott SAN RAFAEL, Calif. , Dec. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several... Read More

ROCTAVIAN is First Gene Therapy for Hemophilia to Receive Approved Federal Price in Germany SAN RAFAEL, Calif. , Nov. 28, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for... Read More

• Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO ® and ROCTAVIAN ® Net Product Revenue Guidance Adjusted for Full-year 2023 • VOXZOGO Now Approved for Children without Age Restrictions in the United States and for Children Aged 4 Months and Older in Europe • ROCTAVIAN Reimbursement Network On-track to Support Global Patient Access and Treatment in 2024 and Beyond; Final German and... Read More

Mr. Hardy Brings More than 30 Years of Industry Experience, Most Recently as CEO of Genentech Mr. Bienaimé Served as CEO for 18 Years and as Chairman since 2015, Steering BioMarin to Profitability with Major Expansion of Commercial Portfolio Richard A. Meier , Current Lead Independent Director, to Become Chair of Board of Directors Transition Effective December 1, 2023 SAN RAFAEL, Calif. , Nov. 1 , 2023 /PRNewswire/ --... Read More

Expanded Indication in the U.S. Now Includes Children of all ages with Achondroplasia SAN RAFAEL, Calif. , Oct. 20, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VOXZOGO ® (vosoritide) to... Read More

SAN RAFAEL, Calif. , Oct. 17 , 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, November 1 , at 4:30 p.m. ET to discuss third-quarter 2023 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-330-3073... Read More

Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4 SAN RAFAEL, Calif. , Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that new data on VOXZOGO ® (vosoritide) in children with achondroplasia will be presented at the 61st Annual European Society for... Read More

European Commission Approval Decision Expected Q4 2023 Opinion Based on Positive Results from Global Phase 2 and Ongoing Extension Study U.S. Food and Drug Administration PDUFA Target Action Date for Supplemental New Drug Application for VOXZOGO for Children Under 5 is Oct. 21, 2023 SAN RAFAEL, Calif. , Sept. 15, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to... Read More

Live Audio Webcast to Begin at 8:00 a.m. Eastern Time SAN RAFAEL, Calif. , Sept. 11, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will update the investor community on the company's research and development portfolio, including early-stage product candidates and new indication opportunities with VOXZOGO and... Read More

BioMarin Leadership and External Medical Experts to Discuss 7 Product Candidates in Clinical Development as well as ROCTAVIAN and VOXZOGO New Indication Opportunities R&D Day to be Webcast Beginning at 8:00 a.m. Eastern Time September 12 th SAN RAFAEL, Calif. , Sept. 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery,... Read More

Citi's 18th Annual BioPharma Conference on September 6 at 3:30pm ET Morgan Stanley 21st Annual Global Healthcare Conference on September 11 at 10:00am ET Baird's 2023 Global Healthcare Conference on September 12 at 1:25pm ET SAN RAFAEL, Calif. , Sept. 5, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that company management will present at three upcoming investor conferences in September. An... Read More

First Person Treated in Germany ; Reimbursement Discussions on Track in France and Italy In the U.S., ROCTAVIAN Now Commercially Available and Hemophilia Treatment Centers Have Begun Screening Eligible Individuals SAN RAFAEL, Calif. , Aug. 30, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that an... Read More

VOXZOGO ® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 Guidance Pivotal Program with VOXZOGO in New, Potential Second Indication, Hypochondroplasia, to Begin in the Fourth Quarter of 2023 U.S. Approval of ROCTAVIAN™ Received in the Second Quarter and Commercial Launch Underway; Commercial Launch in Europe Making Progress Financial Highlights (in millions of U.S.... Read More

SAN RAFAEL, Calif. , July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, July 31 , at 4:30 p.m. ET to discuss second-quarter 2023 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 888-886-7786 International... Read More

ROCTAVIAN is a One-Time, Single-Dose Treatment Available for Adults with Severe Hemophilia A to Control Bleeds ROCTAVIAN's Approval was Based on Durability, Efficacy and Safety Results from the Largest and Longest Phase 3 Study for a Gene Therapy for Hemophilia Majority of Patients Continued to Respond to ROCTAVIAN Treatment over 3 Years Conference Call and Webcast to be Held at 4:30 p.m. Eastern Time on Thursday , June 29,... Read More

New Data to be Presented for ROCTAVIAN from Phase 3 GENEr8-1 Study, Including Data on the Impact of ROCTAVIAN on Quality of Life and Musculoskeletal Health for Adults with Severe Hemophilia A SAN RAFAEL, Calif. , June 22, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced it will present new data from the... Read More

SAN RAFAEL, Calif. , May 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller , Executive Vice President, Chief Financial Officer of BioMarin will present at the Bank of America 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:40pm PT , in Las Vegas , NV. An audio webcast of the presentation will be available live. You can access the webcast at:... Read More

Growth of VOXZOGO ® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 Guidance Full-year 2023 Top-line and Bottom-line Financial Guidance Reaffirmed; ROCTAVIAN™ Net Product Revenue Guidance Adjusted for Full-year 2023 In Germany , Growing Pipeline of People with Severe Hemophilia A Getting Tested for ROCTAVIAN Treatment Eligibility; ROCTAVIAN U.S. Launch Preparations Underway Ahead of... Read More

SAN RAFAEL, Calif. , April 13, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 26 , at 4:30 p.m. ET to discuss first-quarter 2023 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-831-4163... Read More

New Analyses from Phase 2 and Phase 3 Extension Studies Continue to Demonstrate Sustained Improvement in Growth with no Change in Safety Profile SAN RAFAEL, Calif. , March 14, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will present updated data demonstrating the long-term benefit of treatment with VOXZOGO ®... Read More

The Supplemental New Drug Application is Based on Positive Results from Global Randomized Phase 2 Study in Infants and Young Children FDA set PDUFA Target Action Date of October 21, 2023 SAN RAFAEL, Calif. , March 7, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, announced today that the U.S. Food and Drug... Read More

FDA Extends PDUFA Target Action Date to June 30, 2023 SAN RAFAEL, Calif. , March 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that it received notice this afternoon from the U.S. Food and Drug Administration (FDA) that the agency has extended review of the company's Biologics License Application... Read More

Cowen Healthcare Conference on March 8 in Boston Barclays Global Healthcare Conference on March 15 in Miami Jefferies Biotech on the Bay Summit on March 16 in Miami SAN RAFAEL, Calif. , March 2, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming investor conferences in March. Management will present at the Cowen Healthcare Conference on... Read More

VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 Billion In 2023, More than 15% Growth in Total Revenues and Approximately 30% Growth in Net Income Expected Based on Mid-point of Today's Full-year Guidance; VOXZOGO Revenues Expected to More than Double ROCTAVIAN European Commercial Launch and U.S. Launch Preparations Both Underway; 3-year Analysis from Phase 3 ROCTAVIAN Study in Adults... Read More

SAN RAFAEL, Calif. , Feb. 14, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer and Brian Mueller , Executive Vice President, Chief Financial Officer of BioMarin will participate virtually in the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 , at 11:20 a.m. ET . To access the live webcast, please visit:... Read More

SAN RAFAEL, Calif. , Feb. 7, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, February 27 , at 4:30 p.m. ET to discuss fourth quarter and full-year 2022 financial results and provide a general business update. Dial-in Number U.S. / Canada Dial-in Number: 800-831-4163... Read More

Mean Annualized Bleed Rate Reduced by 80% from Baseline and Factor VIII Usage Reduced by 94% in Year 3 Compared to Baseline 92% of Patients off Prophylaxis at the End of Year 3 First Outcomes-Based Agreement (OBA) Recently Signed in Germany ; Additional Agreements Expected to be Signed in Coming Weeks U.S. Food and Drug Administration Pre-License Inspection of Manufacturing Facility Complete SAN RAFAEL, Calif. , Jan. 8, 2023... Read More

SAN RAFAEL, Calif. , Jan. 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé , Chairman and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 , at 10:30 am PT / 1:30 pm ET , in San Francisco, California . To access the live webcast, please visit the investor section of the BioMarin website,... Read More

BioMarin Submits Supplemental New Drug Application to U.S. Food and Drug Administration to Expand Label to Treat Children with Achondroplasia Under the Age of 5 Submissions Based on Favorable Results from Global Randomized Phase 2 Study in Infants and Young Children Demonstrating Increase of Growth Velocity in All Cohorts by Age Potential to Benefit More than 1,000 Eligible Children in U.S. and Europe Action by Health... Read More

FDA No Longer Plans to Hold an Advisory Committee Meeting, as Previously Planned, to Discuss the Biologics License Application (BLA) BioMarin Remains on Track to Host Scheduled Manufacturing Inspections by FDA in the Coming Weeks SAN RAFAEL, Calif. , Nov. 23, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced advancements in the U.S. Food and Drug Administration (FDA) review of the Biologics License... Read More